

DAFTAR PUSTAKA

- Ananthakrishnan, A., Gogineni, V., Saeian, K., 2006. Epidemiology of primary and secondary liver cancers. *Semin. Intervent. Radiol.* 23: 47–63.
- Aravalli, R., 2013. Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. *Diagnostics* 3: 170–191. doi:10.3390/diagnostics3010170
- Asrani, S.K., Devarbhavi, H., Eaton, J., Kamath, P.S., 2019. Burden of liver diseases in the world. *J. Hepatol.* 70: 151–171. doi:10.1016/j.jhep.2018.09.014
- Baron, R., Smithuis, R., Baron, R., 2020. Liver - Masses I - Characterisation [WWW Document]. *Chicago*. URL <https://radiologyassistant.nl/abdomen/liver-masses-i-characterisation> (accessed 1.23.20).
- Bray, F., Ferlay, J., Soerjomataram, I., 2018. Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries 394–424. doi:10.3322/caac.21492
- Bruix, J., Sherman, M., 2011. Management of hepatocellular carcinoma: An update. *Hepatology* 53: 1020–1022. doi:10.1002/hep.24199
- Chang, K., Hwang, Z., Chang, P., Lin, H., Shih, Y., 2019. Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma. *Sci. Rep.* 1–10. doi:10.1038/s41598-019-56545-1
- Choi, J.Y., Lee, J.M., Sirlin, C.B., 2014a. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part I. Development, growth, and spread: Key pathologic and imaging aspects. *Radiology* 272: 635–654. doi:10.1148/radiol.14132361
- Choi, J.Y., Lee, J.M., Sirlin, C.B., 2014b. CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. *Radiology* 273: 30–50. doi:10.1148/radiol.14132362
- Dahlan, M.S. 2013. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. 3rd ed. A. Suslia, ed. Jakarta: Salemba Medika
- Dioguardi Burgio, M., Ronot, M., Bruno, O., Francoz, C., Paradis, V., Castera, L., Durand, F., Soubrane, O., Vilgrain, V., 2016. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. *Liver Transplant.* 22: 1491–1500. doi:10.1002/lt.24615
- El-Serag, H.B., Marrero, J.A., Rudolph, L., Reddy, K.R., 2008. Diagnosis and Treatment of Hepatocellular Carcinoma. *Gastroenterology* 134: 1752–1763. doi:10.1053/j.gastro.2008.02.090
- Ellis, H., 2011. Anatomy of the liver. *Surgery* 29: 589–592. doi:10.1016/j.mpsur.2011.09.012
- Farazi, P.A., DePinho, R.A., 2006. Hepatocellular carcinoma pathogenesis: From genes to environment. *Nat. Rev. Cancer* 6: 684–687. doi:10.1038/nrc1934

- Foley, W.D., Mallisee, T.A., Hohenwarter, M.D., Wilson, C.R., Quiroz, F.A., Taylor, A.J., 2000. Multiphase hepatic CT with a multirow detector CT scanner. *Am. J. Roentgenol.* 175: 679–685. doi:10.2214/ajr.175.3.1750679
- Forner, A., Real, M.I., Varela, M., Bruix, J., 2007. Transarterial chemoembolization for patients with hepatocellular carcinoma. *Hepatol. Res.* 37 Suppl 2: S230-7. doi:10.1111/j.1872-034X.2007.00190.x
- Fowler, K.J., Kielar, A.Z., Mitchell, D.G., Santillan, C.S., Sirlin, C.B., Cui, J., Hong, W., Sy, E., 2018. The LI-RADS ® v2018 Manual Writing Group Members 823.
- Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J.L., Schirmacher, P., Vilgrain, V., 2018. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol.* 69: 182–236. doi:10.1016/j.jhep.2018.03.019
- Gilcrease-Garcia, B., 2020. Hepatocellular carcinoma - fat containing [WWW Document]. URL <https://radiopaedia.org/cases/hepatocellular-carcinoma-fat-containing-1?lang=us> (accessed 2.4.20).
- Gonzalez-Guindalini, F.D., Botelho, M.P.F., Harmath, C.B., Sandrasegaran, K., Miller, F.H., Salem, R., Yaghamai, V., 2013. Assessment of liver tumor response to therapy: Role of quantitative imaging. *Radiographics* 33: 1781–1800. doi:10.1148/rg.336135511
- Gonzalez-guindalini, F.D., Marcos, P., Salem, R., Yaghamai, M.B.A.V., 2013. Assessment of Liver Tumor Response to Therapy : Role of. *Radiographics.rsna.org* 33: 1782–1800.
- Gouripur, G.C., Kaliwal, B.B., 2013. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. *World J. Hepatol.* 9327: 597–618. doi:10.20959/wjpr2016-6447
- Grandhi, M.S., Kim, A.K., Ronnekleiv-Kelly, S.M., Kamel, I.R., Ghasebeh, M.A., Pawlik, T.M., 2016. Hepatocellular carcinoma: From diagnosis to treatment. *Surg. Oncol.* 25: 74–85. doi:10.1016/j.suronc.2016.03.002
- Hennedige, T., Venkatesh, S.K., 2012. Imaging of hepatocellular carcinoma: Diagnosis, staging and treatment monitoring. *Cancer Imaging* 12: 530–547. doi:10.1102/1470-7330.2012.0044
- Hocquelet, A., Seror, O., Blanc, J.F., Frulio, N., Salut, C., Nault, J.C., Trillaud, H., 2017. Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation. *Oncotarget* 8: 32190–32200. doi:10.18632/oncotarget.12921
- Hyun, D., Shin, S.W., Cho, S.K., Park, K.B., Park, H.S., Choo, S.W., Do, Y.S., Choo, I.W., Shin, J.W., Lim, S.J., 2015. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. *Acta radiol.* 56: 1437–1445. doi:10.1177/0284185114560937
- Idée, J.M., Guiu, B., 2013. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. *Crit. Rev. Oncol. Hematol.* 88: 530–549. doi:10.1016/j.critrevonc.2013.07.003

- Kwan, S.W., Fidelman, N., Ma, E., Kerlan, R.K., Yao, F.Y., 2012. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: A radiological-pathological correlation. *Liver Transplant.* 18: 727–736. doi:10.1002/lt.23413
- Lee, J.H., Lee, J.M., Kim, S.J., Baek, J.H., Yun, S.H., Kim, K.W., Han, J.K., Choi, B.I., 2012. Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: Comparison with pathological differentiation. *Br. J. Radiol.* 85: 573–583. doi:10.1259/bjr/86767895
- Lencioni, R., 2010. Loco-Regional Treatment of Hepatocellular Carcinoma. *Hepatology* 52: 762–773. doi:10.1002/hep.23725
- Lencioni, R., Llovet, J.M., 2013. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. *Clin. Cancer Res.* 19: 1312–1314. doi:10.1158/1078-0432.CCR-12-3796
- Li, M., Xin, Y., Fu, S., Liu, Z., Li, Y., Hu, B., Chen, S., Liang, C., Lu, L., 2016. Corona enhancement and mosaic architecture for prognosis and selection between of liver resection versus transcatheter arterial chemoembolization in single hepatocellular carcinomas >5 cm without extrahepatic metastases: An imaging-based retrospective stu. *Med. (United States)* 95: 1–10. doi:10.1097/MD.0000000000002458
- Li, Y., Li, H., Spitsbergen, J.M., Gong, Z., 2017. Males develop faster and more severe hepatocellular carcinoma than females in kras V12 transgenic zebrafish. *Sci. Rep.* 7: 1–10. doi:10.1038/srep41280
- Liu, P., Xie, S.-H., Hu, S., Cheng, X., Gao, T., Zhang, C., Song, Z., 2017. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. *Oncotarget* 8: 68131–68137. doi:10.18632/oncotarget.19245
- Maida, M., Cabibbo, G., Brancatelli, G., Genco, C., Alessi, N., Genova, C., Romano, P., Raineri, M., Giarratano, A., Midiri, M., Cammà, C., 2013. Assessment of treatment response in hepatocellular carcinoma: A review of the literature. *Futur. Oncol.* 9: 845–854. doi:10.2217/fon.13.33
- Meza-Junco, J., Montano-Loza, A.J., Liu, D.M., Sawyer, M.B., Bain, V.G., Ma, M., Owen, R., 2012. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? *Cancer Treat. Rev.* 38: 54–62. doi:10.1016/j.ctrv.2011.05.002
- Miyayama, S., Yamashiro, M., Okuda, M., Yoshie, Y., Nakashima, Y., Ikeno, H., Orito, N., Matsui, O., 2011. Detection of corona enhancement of hypervascular hepatocellular carcinoma by C-arm dual-phase cone-beam CT during hepatic arteriography. *Cardiovasc. Intervent. Radiol.* 34: 81–86. doi:10.1007/s00270-010-9835-9
- Nino-Murcia, M., Olcott, E.W., Jeffrey, R.B., Lamm, R.L., Beaulieu, C.F., Jain, K.A., 2000. Focal liver lesions: Pattern-based classification scheme for enhancement at arterial CT. *Radiology* 215: 746–751. doi:10.1148/radiology.215.3.r00jn03746
- Nishie, A., Yoshimitsu, K., Okamoto, D., Tajima, T., Asayama, Y., Ishigami, K., Kakihara, D., Nakayama, T., Takayama, Y., Shirabe, K., Fujita, N., Honda, H., 2013. CT prediction of histological grade of hypervascular hepatocellular

- carcinoma: Utility of the portal phase. *Jpn. J. Radiol.* 31: 89–98.
doi:10.1007/s11604-012-0149-5
- Oliver, J.H., Baron, R.L., 1996. Helical biphasic contrast-enhanced CT of the liver: Technique, indications, interpretation, and pitfalls. *Radiology* 201: 1–14. doi:10.1148/radiology.201.1.8816509
- Pabst, R., 2011. Anatomy Atlas of Human Edited Volume 2 Lower Limb Trunk , Viscera., 15th ed. Elsevier Ltd, Munich.
- Padhya, K.T., Marrero, J.A., Singal, A.G., 2013. Recent advances in the treatment of hepatocellular carcinoma. *Curr. Opin. Gastroenterol.* 29: 285–292. doi:10.1097/MOG.0b013e32835ff1cf
- Park, J.W., Chen, M., Colombo, M., Roberts, L.R., Schwartz, M., Chen, P.J., Kudo, M., Johnson, P., Wagner, S., Orsini, L.S., Sherman, M., 2015. Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. *Liver Int.* 35: 2155–2166. doi:10.1111/liv.12818
- Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., 2005. Global Cancer Statistics, 2002. *CA. Cancer J. Clin.* 55: 74–108. doi:10.3322/canjclin.55.2.74
- Pinter, M., Hucke, F., Graziadei, I., Vogel, W., Maieron, A., Königsberg, R., Stauber, R., Grünberger, B., Müller, C., Kölblinger, C., Peck-Radosavljevic, M., Sieghart, W., 2012. Advanced-stage hepatocellular carcinoma: Transarterial chemoembolization versus sorafenib. *Radiology* 263: 590–599. doi:10.1148/radiol.12111550
- Poedjomartono, B., Faisal, A., Nurjanah, S., 2020. Transarterial Chemoembolization in Hepatocellular Carcinoma : A Clinical Efficacy Study of Ganoderma Lucidum Extract Polysaccharide Peptide -Glucan 9: 31–35. doi:10.15562/bmj.v9i1.1610
- Poedjomartono, B., Sudarmanta, 2009. Kemoembolisasi Transarterial (TACE) pada Karsinoma Hepatoselular (KHS). *Indones. J. Cancer* III: 117–121.
- Pracht, M., 2012. Comparison of Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) and Modified RECIST in Patients Treated With Sorafenib for Hepatocellular Carcinoma. *Cancer* 147–156. doi:10.1002/cncr.26255
- Sandow, T.A., Arndt, S.E., Devun, D.A., Kirsch, D.S., Gimenez, J.M., Bohorquez, H.E., Gilbert, P.J., Thevenot, P.T., Nunez, K.G., Galliano, G.A., Cohen, A.J., Kay, D., Gulotta, P.M., 2018. Assessment of Response to Transcatheter Arterial Chemoembolization Microspheres : Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort 1. *Radiology* 286.
- Schütte, K., Schulz, C., Malfertheiner, P., 2014. Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment. *Gastrointest. Tumors* 1: 84–92. doi:10.1159/000362583
- Shin, S.W., 2009. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. *Korean J. Radiol.* 10: 425–434. doi:10.3348/kjr.2009.10.5.425
- Sieghart, W., Hucke, F., Peck-Radosavljevic, M., 2015. Transarterial chemoembolization: Modalities, indication, and patient selection. *J. Hepatol.* 62: 1187–1195. doi:10.1016/j.jhep.2015.02.010

- Wu, E.M., Wong, L.L., Hernandez, B.Y., Ji, J.-F., Jia, W., Kwee, S.A., Kalathil, S., 2018. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. *Hepatoma Res.* 4: 66. doi:10.20517/2394-5079.2018.87
- Yang, H.J., Lee, J.H., Lee, D.H., Yu, S.J., Kim, Y.J., Yoon, J.H., Kim, H.C., Lee, J.M., Chung, J.W., Yi, N.J., Lee, K.W., Suh, K.S., Lee, H.S., 2014. Small single-nodule hepatocellular carcinoma: Comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. *Radiology* 271: 909–918. doi:10.1148/radiol.13131760
- Yeo, D.M., Choi, J. Il, Lee, Y.J., Park, M.Y., Chun, H.J., Lee, H.G., 2014. Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. *J. Comput. Assist. Tomogr.* 38: 391–397. doi:10.1097/RCT.0000000000000070
- Zhang, W., Xu, A.H., Wang, W., Wu, Y.H., Sun, Q.L., Shu, C., 2019. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. *BMC Cancer* 19: 1–10. doi:10.1186/s12885-019-6265-1